このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

大腸癌に対するボテンシリマブとバルスチリマブの研究

2026年9月21日 更新者:Memorial Sloan Kettering Cancer Center

手術および化学療法後の持続性循環腫瘍DNAを有する大腸癌患者におけるアジュバントボテンシリマブとバルスチリマブ併用療法の第II相試験

The researchers are doing this study to find out whether the combination of botensilimab and balstilimab (BOT/BAL), followed by balstilimab alone, is an effective treatment for people with microsatellite stable (MSS) colorectal cancer or colorectal liver metastases (CRLM) who have measurable residual disease (MRD) after standard treatment with surgery and chemotherapy or total neoadjuvant therapy (TNT).

調査の概要

詳細な説明

This is a 2-part, 2-cohort each. Part-1 will be a non-randomized study of 54 subjects to assess ctDNA clearance, including 2 cohorts. Cohort 1a includes 27 patients with stage III non-MSI-H/pMMR colorectal cancer following surgery and adjuvant chemotherapy or total neoadjuvant therapy (TNT), with persistent MRD. Cohort 1b includes 27 patients with non-MSI-H/pMMR CRLM following surgery and peri-operative chemotherapy, with persistent MRD.

Part-2 will be a randomized, placebo-controlled, double-blind study of 230 patients with non- MSI-H/pMMR CRC with MRD, to assess RFS. Cohort 2a includes 113 patients with stage III non-MSI-H/pMMR colorectal cancer following surgery and adjuvant chemotherapy or TNT with persistent MRD, randomized 2:1 to treatment versus placebo.

研究の種類

介入

入学 (推定)

284

段階

  • フェーズ2

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

  • 名前:Luis Diaz, MD
  • 電話番号:646-888-4641

研究連絡先のバックアップ

  • 名前:Neil Segal, MD, PhD
  • 電話番号:646-888-4187
  • メール:crc@mskcc.org

研究場所

    • New Jersey
      • Basking Ridge、New Jersey、アメリカ、07920
        • 募集
        • Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)
        • コンタクト:
          • Neil Segal, MD, PhD
          • 電話番号:646-888-4187
      • Middletown、New Jersey、アメリカ、07748
        • 募集
        • Memorial Sloan Kettering Monmouth (Limited Protocol Activities)
        • コンタクト:
          • Neil Segal, MD, PhD
          • 電話番号:646-888-4187
      • Montvale、New Jersey、アメリカ、07645
        • 募集
        • Memorial Sloan Kettering Bergen (Limited Protocol Activities)
        • コンタクト:
          • Neil Segal, MD, PhD
          • 電話番号:646-888-4187
    • New York
      • Commack、New York、アメリカ、11725
        • 募集
        • Memorial Sloan Kettering Commack (Limited Protocol Activities)
        • コンタクト:
          • Neil Segal, MD, PhD
          • 電話番号:646-888-4187
      • Harrison、New York、アメリカ、10604
        • 募集
        • Memorial Sloan Kettering Westchester (All Protocol Activities)
        • コンタクト:
          • Neil Segal, MD, PhD
          • 電話番号:646-888-4187
      • New York、New York、アメリカ、10065
        • 募集
        • Memorial Sloan Kettering Cancer Center (All Protocol Activities)
        • コンタクト:
          • Luis Diaz, MD
          • 電話番号:646-888-4641
        • コンタクト:
          • Neil Segal, MD,PhD
          • 電話番号:646-888-4187
        • 主任研究者:
          • Neil Segal, MD, PhD
      • Rockville Centre、New York、アメリカ、11553
        • 募集
        • Memorial Sloan Kettering Nassau (Limited Protocol Activities)
        • コンタクト:
          • Neil Segal, MD, PhD
          • 電話番号:646-888-4187

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年歳以上 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Inclusion Criteria:

  • Subject or legally authorized representative, is willing and able to provide written informed consent.

  • Histologically- or cytologically- confirmed colorectal cancer.

  • ≥ 18 years of age on day of signing informed consent.

  • Consent for use of archival tissue and blood draws for research purposes.

  • Performance status of ECOG 0 or 1.

  • Known non-MSI-H/pMMR by IHC, PCR or NGS testing. MSKCC confirmation of non-MSI-H/pMMR status is not mandatory prior to enrollment and treatment on the study. For patients with outside testing, if sufficient tissue is available testing may be repeated at MSKCC and will not impact initial eligibility.

  • Consent to undergo MSK IMPACT or NGS, if not previously done

  • Disease specific criteria:

    1. Cohorts 1a and 2a: Undergone a complete surgical resection (R0) for stage III colon or rectal cancer, followed by adjuvant chemotherapy with FOLFOX or CAPEOX. Post-operative chemotherapy not required if received previous oxaliplatin-based therapy. Total Neoadjuvant Therapy for rectal cancer with complete clinical and radiographic response is allowed.
    2. Cohorts 1b and 2b: Undergone a complete surgical resection (R0) for liver metastasis (ablation or stereotactic body radiation therapy [SBRT], but not Y-90, is permitted) and completed standard peri-operative chemotherapy. Peri-operative chemotherapy not required if received previous oxaliplatin-based therapy. Prior floxuridine via Hepatic Arterial Infusion Pump is permitted. Completed definitive treatment for the primary tumor including (R0) resection, or Total Neoadjuvant Therapy for rectal cancer with complete clinical and radiographic response.
  • Positive ctDNA following completion of appropriate standard of care therapy.

  • Patients must sign informed consent within 6 weeks of positive ctDNA result. The 6 weeks is considered from the date that the ctDNA is resulted, and not the date it is drawn.

Adequate organ function, defined as:

  1. Absolute Neutrophil Count ≥ 1,500/mm3.

  2. Platelet count ≥ 75,000/mm3.

  3. Hemoglobin ≥ 9.0 g/dL

  4. Creatinine clearance (CrCl) ≥60 mL/min.

  5. AST and ALT ≤ 2.5 × ULN

  6. Bilirubin ≤ 1.5 × ULN or Direct bilirubin ≤ ULN

    • Subjects of childbearing potential (or with partners of childbearing potential) must use effective contraception for the course of the study starting with the screening visit through at least 5 months after the last dose of study treatment. Appropriate methods of birth control include abstinence, oral contraceptives, implantable hormonal contraceptives, or double barrier method (diaphragm plus condom).

Exclusion Criteria:

  • Presence of metastatic or recurrent disease.

  • Known DNA polymerase epsilon (POLE) or DNA polymerase delta (POLD) activating mutation.

  • R1 (microscopic residual tumor) or R2 resection (macroscopic residual tumor at resection margin).

  • Currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatment.

  • Diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatment.

    1. Patients who have received acute, low dose, systemic immunosuppressant medications (e.g., dexamethasone containing antiemetic regimen or steroids as CT scan contrast premedication) may be enrolled.
    2. The use of inhaled corticosteroids and mineralocorticoids (e.g., fludrocortisone) for patients with orthostatic hypotension or adrenocortical insufficiency is allowed.
  • Hypersensitivity to botensilimab or balstilimab or any of its excipients.

  • Chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study Day 1 or who has not recovered (i.e., ≤ Grade 1 or at baseline) from adverse events due to a previously administered agent

    a. Note: If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy.

  • History of, or any evidence of active, non-infectious pneumonitis.

  • Active infection requiring systemic therapy.

  • Current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the subject's participation for the full duration of the trial, or is not in the best interest of the subject to participate, in the opinion of the treating investigator.

  • Known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.

  • Pregnant or breastfeeding or expecting to conceive or father children within the projected duration of the trial, starting with the pre-screening or screening visit through 90 days after the last dose of trial treatment.

  • Prior therapy with an anti-PD-1, anti-PD-L1, or anti-CTLA-4 agent.

  • Active autoimmune disease or history of autoimmune disease that required systemic treatment within 2 years of the start of study treatment (i.e., with use of disease-modifying agents or immunosuppressive drugs). The following are exceptions:

    1. Subjects with vitiligo or alopecia
    2. Subjects with hypothyroidism (e.g., following Hashimoto syndrome) stable on hormone replacement or psoriasis not requiring systemic treatment
  • Known active TB (Bacillus tuberculosis).

  • Uncontrolled infection with human immunodeficiency virus (HIV). Patients on stable highly active antiretroviral therapy with undetectable viral load and normal CD4 counts for at least 6 months prior to study entry are eligible. Serological testing for HIV at screening is not required

  • Known to be positive for hepatitis B virus (HBV) surface antigen, or any other positive test for HBV indicating acute or chronic infection. Patients who are receiving or who have received anti-HBV therapy and have undetectable HBV DNA prior to study entry are eligible. Serological testing for HBV at screening is not required.

  • Known active hepatitis C virus (HCV) as determined by positive serology and confirmed by polymerase chain reaction (PCR). Patients on or who have received antiretroviral therapy are eligible provided they are virus-free by PCR for at least 6 months prior to study entry. Serological testing for HCV at screening is not required.

  • Received a live vaccine within 30 days of planned start of study therapy

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:ランダム化
  • 介入モデル:並列代入
  • マスキング:ダブル

武器と介入

参加者グループ / アーム
介入・治療
実験的:Cohort 1a: Stage III MSS Colorectal Cancer (Botensilimab and Balstilimab)

All patients will receive botensilimab IV on day 1 of the 42 day cycle for 4 doses, balstilimab IV on days 1, 15, and 29 of the 42 day cycle. Patient then continues balstilimab alone for an additional two cycles IV on days 1, 15, and 29 of the 42 day cycle.

All patients will receive botensilimab IV on day 1 of the 42 day cycle for 4 doses

他の名前:
  • AGEN1181

All patients will receive balstilimab IV on days 1, 15, and 29 of the 42 day cyclePatient then continues balstilimab alone for an additional two cycles IV on days 1, 15, and 29 of the 42 day cycle.

他の名前:
  • AGEN2034
実験的:Cohort 1b: MSS CRLM (Botensilimab and Balstilimab)

All patients will receive botensilimab IV on day 1 of the 42 day cycle for 4 doses, balstilimab IV on days 1, 15, and 29 of the 42 day cycle. Patient then continues balstilimab alone for an additional two cycles IV on days 1, 15, and 29 of the 42 day cycle.

All patients will receive botensilimab IV on day 1 of the 42 day cycle for 4 doses

他の名前:
  • AGEN1181

All patients will receive balstilimab IV on days 1, 15, and 29 of the 42 day cyclePatient then continues balstilimab alone for an additional two cycles IV on days 1, 15, and 29 of the 42 day cycle.

他の名前:
  • AGEN2034
実験的:Cohort 2a: Stage 3 MSS Colorectal Cancer (Botensilimab and Balstilimab vs. Placebo) Randomized

All patients will receive botensilimab IV on day 1 of the 42 day cycle for 4 doses, balstilimab IV on days 1, 15, and 29 of the 42 day cycle. Patient then continues balstilimab alone for an additional two cycles IV on days 1, 15, and 29 of the 42 day cycle OR Placebo

Placebo

All patients will receive botensilimab IV on day 1 of the 42 day cycle for 4 doses

他の名前:
  • AGEN1181

All patients will receive balstilimab IV on days 1, 15, and 29 of the 42 day cyclePatient then continues balstilimab alone for an additional two cycles IV on days 1, 15, and 29 of the 42 day cycle.

他の名前:
  • AGEN2034
実験的:Cohort 2b: MSS CRLM (Botensilimab and Balstilimab vs. Placebo) Randomized

All patients will receive botensilimab IV on day 1 of the 42 day cycle for 4 doses, balstilimab IV on days 1, 15, and 29 of the 42 day cycle. Patient then continues balstilimab alone for an additional two cycles IV on days 1, 15, and 29 of the 42 day cycle OR Placebo

Placebo

All patients will receive botensilimab IV on day 1 of the 42 day cycle for 4 doses

他の名前:
  • AGEN1181

All patients will receive balstilimab IV on days 1, 15, and 29 of the 42 day cyclePatient then continues balstilimab alone for an additional two cycles IV on days 1, 15, and 29 of the 42 day cycle.

他の名前:
  • AGEN2034

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
無再発生存期間(RFS)(コホート2a)
時間枠:1年
1年
無再発生存期間(RFS)(コホート2b)
時間枠:1年
1年
Rate of ctDNA clearance (Cohort 1a)
時間枠:6 months

The 6 months ctDNA clearance will be estimated using the binomial distribution along with exact 95% confidence intervals separately in each cohort.

6 months
Rate of ctDNA clearance (Cohort 1b)
時間枠:6 months

The 6 months ctDNA clearance will be estimated using the binomial distribution along with exact 95% confidence intervals separately in each cohort.

6 months

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

協力者

捜査官

  • 主任研究者:Neil Segal, MD, PhD、Memorial Sloan Kettering Cancer Center

出版物と役立つリンク

研究に関する情報を入力する責任者は、自発的にこれらの出版物を提供します。これらは、研究に関連するあらゆるものに関するものである可能性があります。

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2025年11月7日

一次修了 (推定)

2030年11月1日

研究の完了 (推定)

2030年11月1日

試験登録日

最初に提出

2025年11月10日

QC基準を満たした最初の提出物

2025年11月10日

最初の投稿 (実際)

2025年11月13日

学習記録の更新

投稿された最後の更新 (実際)

2026年9月22日

QC基準を満たした最後の更新が送信されました

2026年9月21日

最終確認日

2026年9月1日

詳しくは

本研究に関する用語

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

はい

IPD プランの説明

Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made beginning 12 months after publication and for up to 36 months post publication. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org.

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

はい

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する